Towards Healthcare
Neuroscience Clinical Trials Market Growth Forecast 2025 to 2034

Neuroscience Clinical Trials Market Future Driven by Precision

The market is expanding due to the increasing prevalence of neurological disorders such as Alzheimer, Parkinson, and epilepsy. Advancements in neuroimaging biomarkers and novel drug development are further driving trial growth.

  • Insight Code: 6066
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: August 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Shivani Zoting is a dedicated research analyst specializing in the healthcare industry. With a strong academic foundation, a B.Sc. in Biotechnology and an MBA in Pharmabiotechnology, she brings a unique blend of scientific understanding and market strategy to her research.

Shivani contributes to Towards Healthcare and plays an active role at Precedence Research, where she focuses on delivering in-depth market intelligence, competitive analysis, and trend forecasting across pharmaceuticals, medical devices, digital health, and healthcare services. Her insights support healthcare companies, investors, and policymakers in making data-backed decisions in a highly regulated and rapidly evolving sector.

Additionally, Shivani collaborates with Statifacts, further expanding her healthcare domain reach by engaging in diverse projects across global markets. Her strength lies in transforming complex clinical and commercial data into strategic narratives that help stakeholders navigate the future of healthcare.

FAQ's

Neuroscience Clinical Trials Market will expand significantly through 2034, fueled by innovation, changing preferences, and advances in clinical research technologies.

Europe is currently leading the neuroscience clinical trials market due to early adoption of innovative trial designs, digital health technologies, and precision medicine approaches.

The neuroscience clinical trials market includes 4 segments by indication/therapeutic area, by therapeutic modality, by clinical phase, and by region.

Key trends include the growth due to the increasing prevalence of neurological disorders such as Alzheimer, Parkinson, and epilepsy.

India Brand Equity Foundation, Food and Drug Administration, U.S. Environmental Protection Agency, European Medicines Agency, and National Medical Products Administration.